CONTENTS

Original Article
Relationship between Genetic Polymorphisms and mRNA Expression of Dihydrofolate Reductase Enzyme in a Healthy Japanese Population
Masayuki HASHIGUCHI, et al. 185
Drug Safety Evaluation Using a Healthcare Information Database: Using Statin-Related Adverse Drug Reactions as Examples
Keiko KONOMURA, et al. 193

Forum
The Present Status and Issues Regarding Contracts for Compensation with Insurance Companies in Investigator-Initiated Clinical Studies at the Osaka University Hospital
Hiromi UMEZOME, et al. 201
Centralization of Reviews by IRBs in University Hospitals: Consideration of Collaborative IRB in University Hospital Clinical Trial Alliance
Kazuhiko MATSUMOTO, et al. 207

Proceedings of the 33rd Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics
Contents 217
“Personalized Medicine to Avoid Severe Adverse Drug Reactions” 219
“Role and Promotion of Child Medication Pharmacists in Japan” 235
“Use of SS-MIX Standardized Storage for Post-Marketing Studies and Clinical Trials” 251

Proceedings of the 19th Training Course in Clinical Pharmacology
“Knowledge of Clinical Pharmacology, An Update”
1. Clinical Pharmacokinetics: Application to Bed Side through Extensive Understanding of the Whole Processes in Human Body
Ichiro IEIRI 268
2. Pharmacogenomics in Clinical Pharmacology
Hirotoshi ECHIZEN 273
3. Chronopharmacology
Akio FUJIMURA 277
Shinya ITO 281
5. Drug-Drug Interactions --With Special Emphasis on Psychotropic Drugs--
Koichi OTANI 286

Report
Report of Trainee of the Foreign Clinical Pharmacology Training Program : No.2
Harumasa NAKAMURA 291
Report of Trainee of the Foreign Clinical Pharmacology Training Program : No.3
Masaya KOSHIZAKA 297

Minutes of JSCPT Administrative Meeting
63E

Drug Information
89E

Information for Authors
91E

Announcements
93E
### Contents of Proceedings of the 33rd Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

“Personalized Medicine to Avoid Severe Adverse Drug Reactions”
1. Personalized Medicine of Antithrombotic Therapy --PK/PD/PGx and Adverse Effect-- Satoshi YAMADA, et al. 219
2. Personalized Therapy of Tyrosine Kinase Inhibitors Masatomo MIURA, et al. 225
3. Personalized Control of Post-Operative Pain Ken-ichi FUKUDA, et al. 229
4. Side Effect of Efavirenz and CYP2B6*6/*6 Shinichi OKA 233

“Role and Promotion of Child Medication Pharmacists in Japan”
Preface Kou KAWADA, et al. 235
1. Present Status of Ward-Based Clinical Pharmacy Practice in Shizuoka Children’s Hospital Tatsuichiro SAKAMOTO 237
2. A Pediatrician’s Hope for Pharmacists at Start on the Educational System of Certified Pharmacist in Pediatric Pharmacology Kou KAWADA 241
3. Pharmacist Education of Pediatric Pharmacotherapy Yoichi ISHIKAWA 244

“Use of SS-MIX Standardized Storage for Post-Marketing Studies and Clinical Trials”
1. SS-MIX: Standardized Healthcare Information Exchange Promotion Project by Ministry, Its Profile and Effectiveness Michio KIMURA 251
2. Postmarketing Studies in Japan: Current Status and Challenges Kiyoshi KUBOTA 257
3. IT Infrastructure and Clinical Study Kiyoteru TAKENOUCHI 259
4. Studies Based on CYP2C19 Genotypes Takahisa FURUTA, et al. 263